XOMA Corp

XOMA

$24.05

Closing

▲3.04%

1D

▲30.00%

YTD

Market cap

$279.60M

52 week high

$26.50

52 week low

$13.48

Volume

7,754

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$279.60M

Analysts' Rating

BUY

Price Target (Mean)

74

Total Analysts

2

P/E

Operating Margin

-697.23%

Beta

0.58

Revenue Growth (Annual)

-84.21%

52 week high

$26.50

52 week low

$13.48

Div. Yield

%

EPS Annual Growth

1.65

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

XOMA Corporation is a biotechnology royalty aggregator. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase I and II. The Company has a portfolio of economic rights and royalty payments associated with partnered pre-commercial therapeutic candidates. Its royalty portfolio includes AFM13, AFM24, AB002 (proCase/E-WE thrombin), AB023 (xisomab, 3G3), AB054, AZD2936, AV-299 (ficlatuzumab), BAY1213790 (osocimab), CMP-001 (vidutolimod), Lysosomal Storage Disorders Enzymes, COM902, DAY101 (tovorafenib), vosaroxin, INCAGN1876, INCAGN1949, INCAGN02390, INCAGN2385, JNJ-63723283 (cetrelimab), MK-4830, MT-0169, CFZ533 (iscalimab), VPM087 (gevokizumab), NIS793, NIR178, G03-52-01, ebopiprant, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ358, RZ402, faricimab (faricimab-svoa), TAK-079 (mezagitamab), Aldoxorubicin, and Arimoclomol. The Company’s subsidiaries include XOMA Technology Ltd., XOMA (US) LLC, and XOMA UK Limited.